Welcome to our dedicated page for Whitehawk Therapeutics SEC filings (Ticker: WHWK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Whitehawk is a clinical-stage oncology therapeutics company focused on antibody-drug conjugate (ADC) cancer treatments, and its filings offer insight into financial results, development plans and corporate activities related to this strategy.
Among the key documents available are current reports on Form 8-K, which Whitehawk has used to furnish press releases announcing quarterly financial results and recent highlights. These filings reference information such as research and development spending, progress toward Investigational New Drug (IND) submissions for ADC programs like HWK-007 and HWK-016, and updates on the company’s three-asset ADC portfolio targeting PTK7, MUC16 and SEZ6.
On this page, users can also locate Whitehawk’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more detailed discussions of the company’s oncology pipeline, risk factors, and financial condition. For investors interested in governance and compensation matters, proxy materials and related filings can provide additional context on board and executive oversight of the ADC development strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major updates without having to parse every page. Real-time updates from the SEC’s EDGAR system ensure that new WHWK filings, including future 10-Ks, 10-Qs and 8-Ks, appear promptly. Users can also review insider transaction reports on Form 4, when available, to see reported trades by directors and officers.
Together, these resources give a structured view of how Whitehawk reports its financial performance, clinical progress and corporate decisions to regulators and the market.
Whitehawk Therapeutics, Inc. granted Chief Scientific Officer David Dornan a stock option to acquire 282,340 shares of common stock at an exercise price of $3.54 per share, expiring on April 1, 2036.
According to the vesting terms, if he continues as a service provider, 25% of the option will vest on the one-year anniversary of the Vesting Commencement Date of April 1, 2026, with the remaining shares vesting in equal monthly installments over the following three years.
Whitehawk Therapeutics, Inc. reported that its Chief Medical Officer, Margaret Dugan, received a grant of stock options covering 283,157 shares of common stock. The options have an exercise price of $3.54 per share and expire on April 1, 2036.
These options were granted as compensation and will vest over four years. Twenty five percent of the shares will vest on the one-year anniversary of the April 1, 2026 vesting commencement date, with the remaining shares vesting in equal monthly installments until fully vested.
Whitehawk Therapeutics, Inc. executive Bryan Ball reported compensation-related equity activity. He exercised 366,532 restricted stock units, receiving the same number of common shares at a price of $0.00 per share. Following this RSU conversion, he directly held 572,551 shares of common stock.
Ball was also granted a new stock option for 250,058 shares of common stock with an exercise price of $3.54 per share, expiring on April 1, 2036. According to the footnotes, RSUs vest 100% one year after the April 1, 2025 vesting commencement date, and the option vests over four years starting April 1, 2026, assuming continued service.
Whitehawk Therapeutics, Inc. reported that Chief Financial Officer Scott M. Giacobello exercised restricted stock units and received a new stock option grant. He exercised 473,902 restricted stock units, receiving the same number of common shares, and now directly holds 502,002 common shares. He was also granted a stock option for 300,677 shares of common stock at an exercise price of $3.54 per share, expiring on April 1, 2036. According to the footnotes, the RSU award vests 100% on the one-year anniversary of the April 1, 2025 vesting commencement date, while the option vests over four years starting from an April 1, 2026 vesting commencement date.
Whitehawk Therapeutics, Inc. director and CEO David James Lennon exercised restricted stock units and received a new stock option award, while selling a small block of shares to cover taxes. He exercised 775,828 restricted stock units, receiving the same number of Common Stock shares. He also received a stock option for 831,148 shares of Common Stock at an exercise price of $3.54 per share, expiring on April 1, 2036, subject to multi‑year vesting. To satisfy tax withholding obligations related to RSU vesting, a broker-assisted sale of 26,858 shares of Common Stock was executed at $3.48 per share. After these transactions, Lennon directly holds 793,549 Common Stock shares.
Whitehawk Therapeutics submitted a Form 144 notice covering proposed sales of Common Stock and Restricted Stock Units.
The filing lists 775,828 Restricted Stock Units with an entry date of 04/01/2026 and reports a prior sale of 5,100 shares on 03/02/2026 for $16,878.96.
Whitehawk Therapeutics is refocusing as a clinical-stage oncology company built around three next-generation antibody-drug conjugates licensed from WuXi Biologics. Lead candidates HWK-007 and HWK-016 have cleared U.S. INDs, with Phase 1 trials recruiting and data readouts expected in the first half of 2027. An IND for HWK-206 is planned for mid-2026.
The company exited its prior FYARRO Business, selling 100% of the FYARRO operating subsidiary to KAKEN for $102.4 million, and no longer commercializes FYARRO. FYARRO generated net product sales of $7.1 million in 2025 and $26.0 million in 2024. Management believes existing cash, cash equivalents and short-term investments can fund planned operations into 2028.
Whitehawk Therapeutics reported full-year 2025 results, highlighting a transition to a pure-play oncology ADC company with three clinical and near-clinical assets. Cash, cash equivalents and short-term investments were $145.7 million as of December 31, 2025, up from $47.2 million a year earlier, and are expected to fund operations into 2028.
Product revenue fell to zero in 2025 from $25.98 million in 2024 following the divestiture of the AADI subsidiary, while net loss narrowed to $20.6 million from $63.7 million, aided by an $87.3 million gain on that sale. The company is actively recruiting Phase 1 trials for PTK7-targeted ADC HWK-007 and MUC16-targeted ADC HWK-016, plans an IND for HWK-206 in mid-2026, and expects initial Phase 1 data for HWK-007 and HWK-016 in the first half of 2027.
Whitehawk Therapeutics CEO David James Lennon reported routine equity compensation activity. He exercised restricted stock units into 16,250 shares of Common Stock at a conversion price of $0.0000 per share on March 1, 2026. On March 2, 2026, 5,100 Common Stock shares were sold at $3.3096 per share in a broker-assisted sale to satisfy tax withholding obligations related to the RSU vesting, rather than a discretionary market sale. After these transactions, he directly holds 44,579 shares of Common Stock and 32,500 restricted stock units.
Whitehawk Therapeutics, Inc. Chief Financial Officer Scott M. Giacobello reported compensation-related stock activity. On March 1, 2026, he exercised restricted stock units, converting 6,750 RSUs into the same number of common shares at a stated price of $0.0000 per share. A related entry shows 13,500 RSUs remaining after this vesting. On March 2, 2026, he completed a broker-assisted sale of 2,594 common shares at an average price of $3.3096 per share to satisfy tax withholding obligations tied to the RSU vesting. Following these transactions, he directly held 28,100 common shares.